Physician profile
Rajeev Tummuru
NPI 1972762540
$4,228.32
in general payments reported to CMS, 2019-2025
25 companies · $727 in 2025
The $727 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $270 · 2021: $389 · 2022: $964 · 2023: $829 · 2024: $606 · 2025: $727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,102 · Education: $60.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,102.24 |
| Education | $60.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,359.89 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Janssen Biotech, INC. | $454.80 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $406.88 | 2019-2025 | Entyvio, Eohilia |
| Celgene Corporation | $390.70 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $365.22 | 2019-2025 | Livdelzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $249.36 | 2019-2023 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $212.73 | 2021-2022 | |
| Madrigal Pharmaceuticals | $181.16 | 2025 | Rezdiffra |
| Eisai INC. | $87.03 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $70.74 | 2023-2025 | Dupixent |
| Pfizer INC. | $59.66 | 2019-2024 | |
| Ironwood Pharmaceuticals, INC | $56.99 | 2019-2020 | |
| Cook Medical LLC | $52.63 | 2019 | |
| Intercept Pharmaceuticals, INC. | $48.83 | 2022-2024 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $39.36 | 2025 | Iqirvo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $31.46 | 2019 | |
| Genzyme Corporation | $29.99 | 2023-2024 | |
| Qol Medical, LLC | $20.75 | 2025 | Sucraid |
| Phathom Pharmaceuticals, INC. | $18.52 | 2024 | Voquezna |
| Nestle Healthcare Nutrition INC. | $16.56 | 2021 | |
| Celltrion USA INC. | $16.50 | 2024 | Vegzelma |
| Shionogi INC | $16.11 | 2020 | |
| Novo Nordisk INC | $15.74 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $13.90 | 2022 | |
| Allergan, INC. | $12.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajeev Tummuru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.